Abstract
Osteogenesis imperfecta is a rare genetic disorder characterized by bone fragility, due to alterations in the type I collagen molecule. It is a very heterogeneous disease, both genetically and phenotypically, with a high variability of clinical phenotypes, ranging from mild to severe forms, the most extreme cases being perinatal lethal. There is no curative treatment for OI, and so great efforts are being made in order to develop effective therapies. In these attempts, the in vivo preclinical studies are of paramount importance; therefore, serious analysis is required to choose the right murine OI model able to emulate as closely as possible the disease of the target OI population. In this review, we summarize the features of OI murine models that have been used for preclinical studies until today, together with recently developed new murine models. The bone parameters that are usually evaluated in order to determine the relevance of new developing therapies are exposed, and finally, current and innovative therapeutic strategies attempts considered in murine OI models, along with their mechanism of action, are reviewed. This review aims to summarize the in vivo studies developed in murine models available in the field of OI to date, in order to help the scientific community choose the most accurate OI murine model when developing new therapeutic strategies capable of improving the quality of life.
Funder
the Instituto de Salud Carlos III (ISCIII)
Health Department, Basque Government
the Spanish Federation of Rare Diseases
AHUCE Foundation
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference179 articles.
1. Osteogenesis imperfecta;Marini;Nat. Rev. Dis. Primers,2017
2. Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types;Jovanovic;Endocr. Rev.,2022
3. Dissecting the phenotypic variability of osteogenesis imperfecta;Garibaldi;Dis. Model. Mech.,2022
4. Osteogenesis imperfecta: An update on clinical features and therapies;Marom;Eur. J. Endocrinol.,2020
5. Botor, M., Fus-Kujawa, A., Uroczynska, M., Stepien, K.L., Galicka, A., Gawron, K., and Sieron, A.L. (2021). Osteogenesis Imperfecta: Current and Prospective Therapies. Biomolecules, 11.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献